Cargando…

Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury

BACKGROUND: Statins cannot be used for some active liver diseases, which limits its application to some extent. The combined use of statins with other drugs may be one of the ways to solve this dilemma. OBJECTIVE: This research aims to evaluate the effects of atorvastatin combined with Panax notogin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qing-Fang, Huang, Min-Yi, Wu, Kang-Yuan, Weng, Jie-Ling, Deng, Rong-Gui, Xu, Xin-Jie, Xu, Jian-Pei, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551361/
https://www.ncbi.nlm.nih.gov/pubmed/28839368
http://dx.doi.org/10.4103/pm.pm_424_16
_version_ 1783256302568341504
author Jiang, Qing-Fang
Huang, Min-Yi
Wu, Kang-Yuan
Weng, Jie-Ling
Deng, Rong-Gui
Xu, Xin-Jie
Xu, Jian-Pei
Jiang, Tao
author_facet Jiang, Qing-Fang
Huang, Min-Yi
Wu, Kang-Yuan
Weng, Jie-Ling
Deng, Rong-Gui
Xu, Xin-Jie
Xu, Jian-Pei
Jiang, Tao
author_sort Jiang, Qing-Fang
collection PubMed
description BACKGROUND: Statins cannot be used for some active liver diseases, which limits its application to some extent. The combined use of statins with other drugs may be one of the ways to solve this dilemma. OBJECTIVE: This research aims to evaluate the effects of atorvastatin combined with Panax notoginseng saponins (PNS) on rats with atherosclerosis (AS) complicated with hepatic injury. MATERIALS AND METHODS: Seventy-two male Wistar rats were randomly categorized into control group (without any intervention, Group A) and AS model groups, which were divided into hepatic injury (Groups B–E) and nonhepatic injury (Groups F–I) groups. Hepatic and nonhepatic injury groups were intragastrically treated with 5.5 mg/kg·d atorvastatin (Group B, F), 200 mg/kg·d PNS (Group C, G), 5.5 mg/kg·d atorvastatin + 200 mg/kg·d PNS (Group D, H), and normal saline (Group E, I). After 8 weeks, total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol, low density lipoprotein-cholesterol (LDL-C), and serum calcium were analyzed to evaluate the hypolipidemic effect. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin, and r-glutamyltransferase levels were measured to assess liver function. The thoracic aortas were used for hematoxylin–eosin staining. RESULTS: In both hepatic injury and nonhepatic injury groups, TC, TG and LDL-C levels significantly decreased in Groups B, D, F, and H. ALT and AST levels significantly increased in Group B, but significantly decreased in Groups C and D. The aortic intima thickness was significantly lower in Groups B, D, F, and H than that in the normal saline group. CONCLUSION: The combination of atorvastatin and PNS treatment showed a significant hypolipidemic effect and hepatic enzyme stability function. SUMMARY: The single use of Panax notoginseng saponins (PNS) in the rat model for atherosclerosis significantly reduced Ca(2+) content in serum, whereas the effect of lowing total cholesterol (TC), triglyceride (TG), and low density lipoprotein-cholesterol (LDL-C) is not apparent, especially as compared with atorvastatin treatment. PNS combined with atorvastatin treatment of the rat model for atherosclerosis displayed a noticeable, synergistic effect that allowed for better reduction of TC, TG, LDL-C and Ca(2+) in the serum than that with the single use of PNS or atorvastatin. In the rat liver injury combined with atherosclerosis model, the single use of PNS significantly improved liver function, whereas atorvastatin alone only aggravated liver injury in the rat model. The effect of PNS combined with atorvastatin on liver function was significantly better than that of atorvastatin alone. The combined use of PNS and atorvastatin showed good stability of liver function on the liver injury combined with atherosclerosis model. Abbreviations used: PNS: Panax notoginseng saponins; AS: Atherosclerosis; TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein-cholesterol; LDL-C: Low density lipoprotein-cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; T-BIL: Total bilirubin; r-GT: R-glutamyltransferase; HE: Hematoxylin–eosin.
format Online
Article
Text
id pubmed-5551361
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-55513612017-08-24 Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury Jiang, Qing-Fang Huang, Min-Yi Wu, Kang-Yuan Weng, Jie-Ling Deng, Rong-Gui Xu, Xin-Jie Xu, Jian-Pei Jiang, Tao Pharmacogn Mag Original Article BACKGROUND: Statins cannot be used for some active liver diseases, which limits its application to some extent. The combined use of statins with other drugs may be one of the ways to solve this dilemma. OBJECTIVE: This research aims to evaluate the effects of atorvastatin combined with Panax notoginseng saponins (PNS) on rats with atherosclerosis (AS) complicated with hepatic injury. MATERIALS AND METHODS: Seventy-two male Wistar rats were randomly categorized into control group (without any intervention, Group A) and AS model groups, which were divided into hepatic injury (Groups B–E) and nonhepatic injury (Groups F–I) groups. Hepatic and nonhepatic injury groups were intragastrically treated with 5.5 mg/kg·d atorvastatin (Group B, F), 200 mg/kg·d PNS (Group C, G), 5.5 mg/kg·d atorvastatin + 200 mg/kg·d PNS (Group D, H), and normal saline (Group E, I). After 8 weeks, total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol, low density lipoprotein-cholesterol (LDL-C), and serum calcium were analyzed to evaluate the hypolipidemic effect. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin, and r-glutamyltransferase levels were measured to assess liver function. The thoracic aortas were used for hematoxylin–eosin staining. RESULTS: In both hepatic injury and nonhepatic injury groups, TC, TG and LDL-C levels significantly decreased in Groups B, D, F, and H. ALT and AST levels significantly increased in Group B, but significantly decreased in Groups C and D. The aortic intima thickness was significantly lower in Groups B, D, F, and H than that in the normal saline group. CONCLUSION: The combination of atorvastatin and PNS treatment showed a significant hypolipidemic effect and hepatic enzyme stability function. SUMMARY: The single use of Panax notoginseng saponins (PNS) in the rat model for atherosclerosis significantly reduced Ca(2+) content in serum, whereas the effect of lowing total cholesterol (TC), triglyceride (TG), and low density lipoprotein-cholesterol (LDL-C) is not apparent, especially as compared with atorvastatin treatment. PNS combined with atorvastatin treatment of the rat model for atherosclerosis displayed a noticeable, synergistic effect that allowed for better reduction of TC, TG, LDL-C and Ca(2+) in the serum than that with the single use of PNS or atorvastatin. In the rat liver injury combined with atherosclerosis model, the single use of PNS significantly improved liver function, whereas atorvastatin alone only aggravated liver injury in the rat model. The effect of PNS combined with atorvastatin on liver function was significantly better than that of atorvastatin alone. The combined use of PNS and atorvastatin showed good stability of liver function on the liver injury combined with atherosclerosis model. Abbreviations used: PNS: Panax notoginseng saponins; AS: Atherosclerosis; TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein-cholesterol; LDL-C: Low density lipoprotein-cholesterol; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; T-BIL: Total bilirubin; r-GT: R-glutamyltransferase; HE: Hematoxylin–eosin. Medknow Publications & Media Pvt Ltd 2017 2017-07-19 /pmc/articles/PMC5551361/ /pubmed/28839368 http://dx.doi.org/10.4103/pm.pm_424_16 Text en Copyright: © 2017 Pharmacognosy Magazine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Jiang, Qing-Fang
Huang, Min-Yi
Wu, Kang-Yuan
Weng, Jie-Ling
Deng, Rong-Gui
Xu, Xin-Jie
Xu, Jian-Pei
Jiang, Tao
Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury
title Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury
title_full Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury
title_fullStr Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury
title_full_unstemmed Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury
title_short Intervention Effects of Atorvastatin Combined with Panax notoginseng Saponins on Rats with Atherosclerosis Complicated with Hepatic Injury
title_sort intervention effects of atorvastatin combined with panax notoginseng saponins on rats with atherosclerosis complicated with hepatic injury
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551361/
https://www.ncbi.nlm.nih.gov/pubmed/28839368
http://dx.doi.org/10.4103/pm.pm_424_16
work_keys_str_mv AT jiangqingfang interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT huangminyi interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT wukangyuan interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT wengjieling interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT dengronggui interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT xuxinjie interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT xujianpei interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury
AT jiangtao interventioneffectsofatorvastatincombinedwithpanaxnotoginsengsaponinsonratswithatherosclerosiscomplicatedwithhepaticinjury